Dare Bioscience (NASDAQ: DARE) grants CAO 49,000 options

Rhea-AI Filing Summary

Dare Bioscience, Inc. reported that its Chief Accounting Officer, MarDee Haring-Layton, received an employee stock option grant. The award covers 49,000 options to purchase common stock at an exercise price of $1.81 per share, granted on January 30, 2026.

The option vests in 48 equal monthly installments starting one month after the grant date, conditioned on her continuous service with the company. Following this grant, she holds 49,000 derivative securities directly in the form of these stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Haring-Layton MarDee

(Last) (First) (Middle)

C/O DARE BIOSCIENCE, INC.

3655 NOBEL DRIVE, SUITE 260

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dare Bioscience, Inc. [ DARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.81	01/30/2026		A		49,000		(1)	01/30/2036	Common stock	49,000	$0	49,000	D

Explanation of Responses:

1. This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer.

Remarks:

	/s/ MarDee Haring-Layton	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dare Bioscience (DARE) disclose in this Form 4 filing?

Dare Bioscience disclosed an option grant to its Chief Accounting Officer. She received 49,000 employee stock options on January 30, 2026, giving the right to buy common shares at a $1.81 exercise price, subject to a four-year monthly vesting schedule.

Who is the insider in the Dare Bioscience (DARE) Form 4 and what is their role?

The insider is MarDee Haring-Layton, Chief Accounting Officer of Dare Bioscience. She is an officer but not a director or 10% owner. The filing reports a grant of employee stock options awarded to her in connection with her service to the company.

How many Dare Bioscience (DARE) stock options were granted to the CAO?

The Chief Accounting Officer received 49,000 employee stock options. These options give her the right to purchase 49,000 shares of Dare Bioscience common stock, subject to vesting, at an exercise price of $1.81 per share as detailed in the Form 4.

What is the exercise price and vesting schedule of the Dare Bioscience (DARE) options?

The employee stock options have an exercise price of $1.81 per share. They vest and become exercisable in 48 equal monthly installments, beginning one month after the January 30, 2026 grant date, contingent on her continuous service with Dare Bioscience.

When do the Dare Bioscience (DARE) stock options granted to the CAO expire?

The reported employee stock options expire on January 30, 2036. This provides a 10-year term from the January 30, 2026 grant date, during which, once vested, the Chief Accounting Officer may choose to exercise them at the stated $1.81 exercise price.

How many Dare Bioscience (DARE) derivative securities does the insider hold after this transaction?

After this grant, the insider beneficially owns 49,000 derivative securities directly. These are all employee stock options for Dare Bioscience common stock, reflecting the full amount of the January 30, 2026 award reported in the Form 4 filing.